|Day's range||0.1500 - 0.1500|
Merck (MRK) closed the most recent trading day at $78.72, moving -1.08% from the previous trading session.
Merck Announces New Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
Warren Buffett makes it look so easy: find high-quality companies, wait for a fair price to buy, and then hold them... forever. The problem of course is that t...
A look at the shareholders of Merck & Co., Inc. (NYSE:MRK) can tell us which group is most powerful. Institutions...
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
FDA approves Merck's (MRK) Keytruda for first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
FDA Approves Merck’s KEYTRUDA® for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC).
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
Merck's (MRK) development program on V114 comprises 16 studies, evaluating safety, tolerability and immunogenicity of V114 in a variety of patient populations.
V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults.
KEYTRUDA® Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's accelerated approval.
Merck's (MRK) type 2 diabetes drug, Steglatro, achieves primary endpoint of non-inferiority in major adverse CV events compared to placebo in a late-stage cardiovascular outcomes study.
FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA (pembrolizumab), Regardless of Tumor Type
Merck and Pfizer’s SGLT2 Inhibitor STEGLATRO Meets Primary Endpoint in VERTIS CV Trial for Patients with Type2 Diabetes and Atherosclerotic CV Disease